

The Copper *bis*(thiosemicarbazone) Complex Cu^{II}(atsm) Is Protective Against Cerebral Ischemia Through Modulation of the Inflammatory Milieu

Mikko T. Huuskonen¹ · Qing-zhang Tuo^{2,3} · Sanna Loppi¹ · Hiramani Dhungana¹ · Paula Korhonen¹ · Lachlan E. McInnes⁴ · Paul S. Donnelly⁴ · Alexandra Grubman⁵ · Sara Wojciechowski¹ · Katarina Lejavova¹ · Yuriy Pomeschchik¹ · Laura Periviita¹ · Lotta Kosonen¹ · Martina Giordano¹ · Frederick R. Walker⁶ · Rong Liu² · Ashley I. Bush³ · Jari Koistinaho¹ · Tarja Malm¹ · Anthony R. White^{3,5,7,8} · Peng Lei^{3,9,10} · Katja M. Kanninen¹

© The American Society for Experimental NeuroTherapeutics, Inc. 2016

Abstract Developing new therapies for stroke is urgently needed, as this disease is the leading cause of death and disability worldwide, and the existing treatment is only available for a small subset of patients. The interruption of blood flow to the brain during ischemic stroke launches multiple immune

responses, characterized by infiltration of peripheral immune cells, the activation of brain microglial cells, and the accumulation of immune mediators. Copper is an essential trace element that is required for many critical processes in the brain. Copper homeostasis is disturbed in chronic neurodegenerative

Mikko T. Huuskonen, Qing-zhang Tuo, Anthony R. White, Peng Lei and Katja M. Kanninen contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s13311-016-0504-9) contains supplementary material, which is available to authorized users.

✉ Anthony R. White
tony.white@qimrberghofer.edu.au; arwhite@unimelb.edu.au

✉ Peng Lei
peng.lei@scu.edu.cn; peng.lei@florey.edu.au; plei1984@163.com

✉ Katja M. Kanninen
katja.kanninen@uef.fi

Mikko T. Huuskonen
mikko.huuskonen@uef.fi

Qing-zhang Tuo
tqzh1220@163.com

Sanna Loppi
sanna.loppi@uef.fi

Hiramani Dhungana
hiramani.dhungana@uef.fi

Paula Korhonen
paula.korhonen@uef.fi

Lachlan E. McInnes
l.mcinnis2@student.unimelb.edu.au

Paul S. Donnelly
pauld@unimelb.edu.au

Alexandra Grubman
alexandra.grubman@monash.edu

Sara Wojciechowski
sara.wojciechowski@uef.fi

Katarina Lejavova
klejavova@yahoo.com

Yuriy Pomeschchik
yuriy.pomeschchik@uef.fi

Laura Periviita
laurap@student.uef.fi

Lotta Kosonen
lotkos@student.uef.fi

Martina Giordano
martigio@student.uef.fi

Frederick R. Walker
rohan.walker@newcastle.edu

Rong Liu
rong.liu@hust.edu.cn

Ashley I. Bush
ashleyib@unimelb.edu.au

diseases and altered in stroke patients, and targeted copper delivery has been shown to be protective against chronic neurodegeneration. This study was undertaken to assess whether the copper *bis*(thiosemicarbazone) complex, Cu^{II}(atsm), is beneficial in acute brain injury, in preclinical mouse models of ischemic stroke. We demonstrate that the copper complex Cu^{II}(atsm) protects neurons from excitotoxicity and N2a cells from OGD *in vitro*, and is protective in permanent and transient ischemia models in mice as measured by functional outcome and lesion size. Copper delivery in the ischemic brains modulates the inflammatory response, specifically affecting the myeloid cells. It reduces CD45 and Iba1 immunoreactivity, and alters the morphology of Iba1 positive cells in the ischemic brain. Cu^{II}(atsm) also protects endogenous microglia against ischemic insult and reduces the proportion of invading monocytes. These results demonstrate that the copper complex Cu^{II}(atsm) is an inflammation-modulating compound with high therapeutic potential in stroke and is a strong candidate for the development of therapies for acute brain injury.

Key Words Cu^{II}(atsm) · Stroke · Microglia · Neuron · Neuroinflammation

Jari Koistinaho
jari.koistinaho@uef.fi

Tarja Malm
tarja.malm@uef.fi

- ¹ Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
- ² Key Laboratory of Ministry of Education of China for Neurological Disorders, Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- ³ Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
- ⁴ School of Chemistry and Bio21 Institute for Molecular Science and Biotechnology, The University of Melbourne, Parkville, Victoria, Australia
- ⁵ Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia
- ⁶ School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia
- ⁷ Present address: QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
- ⁸ Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Locked Bag 2000, Herston, QLD 4029, Australia
- ⁹ Department of Neurology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- ¹⁰ Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China

Introduction

Ischemic stroke, caused by blockage of blood flow in the brain, is a leading cause of death and long-term disability because of limited therapeutic interventions that are available in clinics. Despite significant efforts, drugs that have the potential to limit neuronal damage after the onset of ischemic stroke have not been discovered. The lack of efficient therapeutics for stroke is largely related to the poor translation of preclinical results into clinics. Due to the heterogeneity of stroke types, this disorder is challenging to model in laboratory settings, and results gained from one preclinical model rarely represent stroke in a broad number of patients.

The interruption of blood flow to the brain during ischemic stroke launches multiple immune responses, which are characterized by infiltration of peripheral immune cells, the activation of resident brain immune cells, and the accumulation of immune mediators [1]. Microglia, the resident immune cells of the brain, are a heterogeneous group of cells that have multiple roles in promoting and modulating brain functions under physiological conditions, including phagocytosis of debris or dying cells, neurogenesis and synaptic modulation [2, 3]. Microglia also have the potential to contribute to the neurological outcome of brain injury [4]. During acute brain injury, microglia rapidly undergo dramatic morphological and phenotypic changes. Considering the heterogeneous nature of microglia, it is not surprising that studies assessing the effect of microglia on stroke outcome have yielded controversial results. In any case, neuroinflammation and blood brain barrier disruption are critical steps in the loss of the neuroglia-vascular network integrity and exacerbation of ischemic damage, and activated microglia are a driving factor in these phenomena [5]. They up-regulate the expression of particular cell surface antigens and produce inflammatory mediators such as tumor necrosis factor (TNF), which can promote neurotoxicity [6]. However, microglia also possess several beneficial functions in stroke, including the promotion of neurogenesis and production of neurotrophic factors [7]. Furthermore, ablation of microglia has been shown to exacerbate ischemic injury in the brain [8].

Copper is an essential trace element that is required for many critical processes in the brain [9]. While copper homeostasis is disturbed in chronic neurodegenerative diseases such as Alzheimer's disease (AD) [10], little is known about copper homeostasis in acute ischemic stroke. Several years ago, Kodali et al. reported an increase in the plasma copper concentrations of ischemic stroke patients [11]. This observation was supported by a recent paper demonstrating that serum levels of both total copper and copper loosely bound to small molecules are elevated in serum of ischemic stroke patients [12]. These papers provide evidence for copper dyshomeostasis upon ischemic damage in patients. In mouse models, chronic intake of copper has been reported to

aggravate ischemic damage, an effect attributed to reduction of angiogenesis [13].

Restoration of brain copper homeostasis is protective against chronic neurodegeneration in animal models of disease [14]. The copper *bis*(thiosemicarbazones) are stable, lipophilic neutral copper(II) complexes that are capable of crossing both cell membranes and the blood brain barrier [15, 16]. These metal delivery and redistribution agents are neuroprotective in animal models of AD, Parkinson's disease, and amyotrophic lateral sclerosis [17–20]. Furthermore, we have recently demonstrated that Cu^{II}(atsm) reduces brain inflammation caused by peripheral administration of bacterial lipopolysaccharide, and that copper delivery is anti-inflammatory in the chronic neuroinflammatory milieu of AD model mice (Choo et al. submitted). To our knowledge, therapeutic approaches targeted to modulation of copper homeostasis in ischemic stroke, where significant neuroinflammation takes place, have not previously been tested.

To address the issue of poor translation of stroke therapeutics into human patients, in this study we tested the copper complex Cu^{II}(atsm) in both permanent and transient ischemia mouse models, and characterized the inflammatory responses after delivery of copper in the ischemic brains. We demonstrate that Cu^{II}(atsm) is protective in both permanent and transient ischemia models, and that copper delivery in the ischemic brains modulates the inflammatory response, specifically affecting the myeloid cells. These results demonstrate that Cu^{II}(atsm) is a compound with high therapeutic potential in stroke and is a strong candidate for the development of therapies for acute brain injury.

Materials and Methods

Cortical Neuron Cultures and Excitotoxicity Assay

Primary cortical neuron cultures were prepared from E15 embryos. Cortices were dissected, after which tissues were dissociated with trypsin (0.0125% for 15 min at 37 °C, Sigma-Aldrich, St. Louis, MO, USA). Neurons were counted and plated on poly-d-lysine (Sigma-Aldrich, St. Louis, MO, USA) coated 48-well plates at a density of 150,000 cells/well in Neurobasal media containing 2% B27, 500 µM l-glutamine and 1% penicillin–streptomycin (all ThermoFisher Scientific, Waltham, MA, USA). 50% of the medium was changed four days after plating and cultures were used for experiments on days 6–7 *in vitro*.

Treatment of cortical neurons was carried out in 50% fresh Neurobasal medium containing 2% B27, 500 µM l-glutamine and 1% penicillin–streptomycin and 50% media collected from the cells. Neurons were treated with 1 µM Cu^{II}(atsm) prepared as above and/or 400 µM glutamate (Sigma-Aldrich, St. Louis, MO, USA) for 24 h prior to measurement of cell viability by the MTT assay.

N2a Cell Cultures and Oxygen-Glucose Deprivation (OGD)

Mouse neuroblastoma 2a cell line (N2a) was cultured on standard cell culture dishes in Dulbecco's Modified Eagle Medium with GlutaMAX-1 containing D-glucose (4.5 g/L) and sodium pyruvate (0.11 g/L) supplemented with 10% heat inactivated FBS and 1% penicillin–streptomycin (all ThermoFisher Scientific, Waltham, MA, USA). For experiments, cells were plated on 48-well plates (coated similarly as the plates for primary cortical neurons) at the density of 37,500 cells/well. 24 h after plating, media was replaced with DMEM without glucose and sodium pyruvate but supplemented as the culture media (ThermoFisher Scientific, Waltham, MA, USA). The plate was then placed into an incubator with 1% oxygen and 5% carbon dioxide (ProOx C21, Biospherix Ltd, Parish, NY, USA). A control plate was maintained in culture media in a regular incubator. Passages 10–14 were used for the experiments.

MTT Viability Assay

The MTT reduction assay was performed 24 hours after exposure to glutamate or OGD according to Denizot & Lang [21] with the following modifications. Briefly, following removal of the media (3-(4, 5-dimethylthiazolyl)-2, 5-diphenyltetrazolium bromide) was added to cells at a concentration of 120 µM, after which the cells were incubated for 2 hours at 37 °C at 5% CO₂. Following removal of the media cells were dissolved in DMSO. The absorbances were read at 585 nm with a Wallac Victor² 1420 multilabel counter (PerkinElmer Inc, Waltham, MA, USA). The results were calculated as relative absorbances compared to the control wells. All cell viability assays were repeated three times with six replicates in each treatment group.

Mice

All animal experiments were approved by the National Animal Experiment Board of Finland and followed the Council of Europe Legislation and Regulation for Animal Protection, or by the Florey Institute animal ethics committee (15-019) and were performed in accordance with the National Health and Medical Research Council Australia guidelines. Mice were housed in individual cages in conditions of controlled humidity, temperature, and light conditions. Water and food were provided *ad libitum*. Three- to seven-month old male Balb/cOlaHsd mice (Harlan Laboratories B.V., An Venrey, Netherlands) were used for the permanent ischemia studies and 3-month old male C57Bl/6Arc mice (Animal Resources Centre, Western Australia) for the transient ischemia studies. Mice were randomized into treatment groups using GraphPad QuickCalcs (GraphPad Software, San

Diego, CA, USA), and all the analyses were performed blinded to the experimental groups.

Ischemia Surgeries and Treatment of Mice with Cu^{II}(atsm)

Transient acute focal cerebral ischemia was induced by the intraluminal middle cerebral artery occlusion (MCAO) as described previously [22, 23]. Mice were deeply anaesthetized with 5% isoflurane in 30% O₂/70% N₂O using the Anesthesia system (Mediquip, Australia). The level of isoflurane was then reduced and maintained at 1%. A 4-mm distal nylon monofilament (30 mm in length, 0.16 mm in diameter, Amber, Japan) segment was coated with 0.21–0.22 mm diameter silicone (Henkel, Australia). MCAO was performed by insertion of the monofilament via the common carotid artery into the left internal carotid artery, advanced 9–10 mm past the carotid bifurcation until a slight resistance was felt. The filament was left in place for 60 min, and then withdrawn for reperfusion. In the sham-operated animals, the occluding filament was inserted only 5 mm above the carotid bifurcation. Mice were excluded from further studies if excessive bleeding occurred during surgery, if the operation time exceeded 90 min, if the mouse failed to recover from anesthesia within 15 min, or if hemorrhage was found in the brain slices or at the base of the circle of Willis during postmortem examination.

For permanent occlusion of the MCA, mice were deeply anesthetized with 5% isoflurane in 30% O₂/70% N₂O and the anesthesia was maintained at 2% during the surgery. The left MCA was permanently occluded as previously described [24]. Briefly, first the temporal bone was first exposed and a 1-mm-diameter hole was drilled to expose the artery. The dura was removed, after which the artery was lifted and occluded by a thermocoagulator (Aaron Medical Industries Inc., Clearwater, FL, USA). MCA occlusion was confirmed by cutting the artery, after which the temporal muscle was replaced and the wound was sutured. The body temperatures of animals were maintained at 37 ± 0.5 °C throughout the procedures using a heat-pad. The temperature and respiratory rates were monitored during the surgery. The sham mice went through all the same procedures except the occlusion of the MCA. The exclusion criteria were predetermined; mice with hemorrhages visible in magnetic resonance imaging (MRI), bleeding during the surgery, and unsuccessful induction of ischemia were excluded.

Cu^{II}(atsm) was prepared according to published procedures [25]. The mice were treated with Cu^{II}(atsm) dissolved in standard suspension vehicle (SSV) solution containing 0.9% (w/v) NaCl, 0.5% (w/v) sodium carboxymethylcellulose, 0.5% (v/v) benzyl alcohol, 0.4% (v/v) Tween 80, or SSV alone by oral gavage. For the transient MCAO mice were treated daily at a dose of 15 mg/kg while for the permanent MCAO the mice were treated daily at a dose of 60 mg/kg. Mice were sacrificed

at 1 or 3 days post injury (dpi) and tissues were collected as described below.

Post-Surgery Evaluation of Outcome

After 24 h of transient MCAO induction, neurological deficits of three mice in each treatment group were evaluated by a simple scale (five-point scale) as described previously [26]: 0, no observable deficit; 1, right forelimb flexion; 2, decreased resistance to left lateral push (and right forelimb flexion) without circling; 3, same behavior as grade 2, with circling to right; 4, severe rotation progressing into barreling, loss of walking or righting reflex. Two investigators blinded to the experimental groups performed the neurological assessment post-surgery.

At 1 dpi the locomotor activity of the mice subjected to permanent MCAO was assessed by the latency-to-move test as previously described [27]. The mice (8–12 in each treatment group) were placed on a flat surface and the time to move one body length (7 cm) was recorded by an investigator blinded to the treatment groups. Each mouse received two trials.

Measurement of Lesion Volume

TTC staining was used to quantify the lesion size following transient ischemia using three animals in each treatment group. 24 hours after the induction of MCAO the mice were euthanized with an overdose of sodium pentobarbitone (Lethobarb, 100 mg/kg). The brain was removed rapidly and frozen at −20 °C for 20 min. Coronal slices were made at 2 mm intervals from the frontal poles, and sections were immersed in 0.5% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich, St. Louis, MO, USA) in phosphate buffered saline (PBS) at 37 °C for 20 min. The presence or absence of infarction was determined by examining TTC-stained sections for the areas on the side of infarction that did not stain with TTC. The brain slices were fixed in 4% paraformaldehyde at 4 °C until imaging. Serial sections were photographed using a digital camera and the area of infarct was quantified with Image J (1.49 m, NIH) by an investigator blinded to the experimental groups. The area of infarct, the area of ipsilateral hemisphere, and the area of the contralateral hemisphere were measured for each section by a blinded operator. The volume was calculated by summing the representative areas in all sections and multiplying by the slice thickness, then correcting for edema, as previously described [28]: *Corrected Infarct Volume (CIV) = contralateral hemisphere volume – (ipsilateral hemisphere volume – infarct volume)*.

MRI imaging was utilized to determine the lesion volume following permanent MCAO. A vertical 9.4 T Oxford NMR 400 magnet (Oxford Instrument PLC, Abington, UK) was used for visualizing the lesion as previously described [24].

The mice were anesthetized with 5% isoflurane in 30% O₂/70% N₂O and multislice T2-weighted images (repetition time 3000 ms, echo time 40 ms, matrix size 128 × 256, field of view 19.2 × 19.2 mm², slice thickness 0.8 mm and number of slices 12) were obtained. The images were analyzed using in-house made software Aedes in the Matlab environment (Math-works, Natick, MA, USA). The infarction volume was calculated as previously described by using the following formula: *Infarct volume* = (volume of left hemisphere – (volume of right hemisphere – measured infarct volume)) / volume of left hemisphere [29].

Immunohistochemistry

Mice were euthanized at 1 (7–8 mice/treatment group) or 3 dpi (5–8 mice/treatment group) for tissue collection. Mice were anesthetized with 250 mg/kg Avertin and perfused transcardially with heparinized (2500 IU/L) saline. The brains were removed and post-fixed in 4% paraformaldehyde for 20 h, after which they were cryoprotected for 48 h in 30% sucrose solution, frozen in liquid nitrogen and cut into 20-μm thick sections with a cryostat (Leica Microsystems, Wetzlar, Germany). Six sections at an interval of 400 μm were selected for immunohistological staining.

The brain sections were incubated overnight at room temperature with primary antibodies (CD45, 1:100 dilution, Bio-Rad, Hercules, CA, USA; CD68, 1:2000 dilution, Bio-Rad, Hercules, CA, USA; GFAP, 1:500 dilution, ABR Affinity BioReagents, Golden, CO, USA; Iba-1, 1:250 dilution, Wako Chemicals, Tokyo, Japan; Ly6-G neutrophil, 1:100 dilution, BioLegend, San Diego, CA, USA; phospho-p38, 1:100 dilution, Cell Signaling Technology, Inc., Danvers, MA, USA). All stainings except the Ly6-G neutrophil stain required antigen retrieval in 10 mM aqueous solution of sodium citrate dihydrate (pH 6, preheated to 92 °C) before application of primary antibodies. Secondary antibodies were applied on sections after three washes in 0.05% Tween20 in PBS. Fluorescent Alexa 568-conjugated secondary antibody (1:200 dilution, Abcam, Cambridge, UK) was used with CD45 and CD68, and 488-conjugated secondary antibody with Iba-1, Ly6G and GFAP. With the phospho-p38 staining, biotinylated secondary antibody (1:200 dilution, Vector Laboratories, Burlingame, CA, USA) was used instead of a fluorescent one, followed by reaction with avidin-biotin complex reagent (1:200 dilution, Vector Laboratories, Burlingame, CA, USA) according to manufacturer's instructions. The bound immunoreactivity was then visualized by development with nickel-enhanced 3,3'-diaminobenzidine.

For quantification of CD68, GFAP, Iba-1 immunoreactivities in the peri-ischemic area, a 718 × 532 μm cortical area adjacent to the infarct border was imaged using 10x magnification on an AX70 microscope (Olympus corporation, Tokyo, Japan) with an adjacent digital camera (Color View 12 or

F-View, Soft imaging system, Muenster, Germany) running AnalySis software (Soft Imaging System). For CD45 and neutrophil stainings, images of equal size were taken from the lesion area, where the majority of the immunoreactivity was observed. Quantification of the immunoreactivities was performed blinded to the study groups using ImagePro Plus software (Media Cybernetics, Rockville, MD, USA) at a predefined range and presented as relative immunoreactive area.

Measurement of Cell Morphology

The morphological reconstitution of Iba1 positive cells at 1 dpi was carried out by Matlab v2013b as described [30, 31]. Several characteristics of the segmented cell processes and cell bodies were analyzed, including area, perimeter and diameter. The images for morphological assessment were taken by a Zeiss LSM 700 confocal microscope (Zeiss Inc., Maple Grove, USA) with an attached digital camera (Color View 12 or F-View; Soft Imaging System, Munster, Germany) running Zen 2012 Image analysis Software (Zeiss inc., Maple Grove, USA).

Cytokine Measurement

Cytokine concentrations were measured in the brain tissues of mice (5–6/treatment group) subjected to permanent MCAO. The mice were sacrificed as described above and following dissection of the peri-ischemic brain area, the samples snap frozen in liquid nitrogen were first homogenized in 20 mM Tris-HCl (pH 7.4), 8.56% sucrose, 0.5 mM EDTA, 0.5 mM EGTA and protease inhibitor cocktail (Complete, Roche Applied Science). The protein levels of IL-6, IL-10, MCP-1, IFN-γ, TNF and IL-12p70 were then measured using the mouse anti-inflammatory cytokine bead array (CBA) kit (BD Biosciences, San Jose, CA, USA), running the samples on a FACS Calibur flow cytometer (BD Biosciences). The results were analyzed using FCAP Array 2.0 software (Soft Flow Hungary Ltd, Pecs, Hungary). Total protein concentrations of the brain samples were determined by Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc, Hercules, CA, USA) and the results of the CBA assay were normalized to the total protein concentrations.

Measurement of Brain Copper Content

Inductively coupled mass spectrometry (ICP-MS) was used to measure copper levels in peri-ischemic brain areas as reported previously [21]. Briefly, cell pellets collected for copper analysis (4–6/treatment group) were digested overnight in concentrated nitric acid (Aristar, BDH, Kilsyth, VIC, Australia), after which samples were heated for 20 min at 90 °C. The volume of each sample was reduced to approximately 40–50 μl then

1 ml of 1% (v/v) nitric acid diluent was added to the samples. Measurements were made using an Agilent ICPMS 7700x series ICP-MS instrument. Results were expressed as micro-mole per liter concentrations of copper ($\mu\text{mol/l}$).

Brain Cell Isolation and Flow Cytometry

Mice (4–6/treatment group) were transcardially perfused at 3 dpi with heparinized saline as above. Brains without cerebellum were isolated and put in HBSS on ice. The tissue was minced on ice with forceps in petri dishes in digest buffer containing 0.5 mg/ml collagenase type 4 (Worthington, Lakewood, NJ, USA) DNase 1, 25 U/ml, and RPMI-1640 (both from Sigma-Aldrich) then incubated at 37 °C, 5% CO₂ for 20 min. Samples were put directly back on ice, triturated, and sequentially filtered through 70 μm and 40 μm cell strainers (Falcon, Corning, NY, USA). Homogenates were centrifuged 450 $\times$ g for 5 min and resuspended in Miltenyi Myelin Debris Removal Beads II (Miltenyi, Cologne, Germany). Samples were incubated for 15 min at 4 °C then washed with cold MACS buffer (PBS and 0.5% BSA, both from Sigma) and centrifuged at 400 $\times$ g for 10 min. Pellets were resuspended in cold MACS buffer and applied to magnetic LD columns (Miltenyi) with 50 μm CellTrics pre-filters (Sysmex, Norderstedt, Germany). The flow-through was collected on ice, counted, then spun 400 $\times$ g for 10 min and resuspended in RPMI-1620.

Cell surface staining was done on 200,000–300,000 cells per mouse in round bottom polypropylene 96-well plates (Corning). Cells were washed with PBS, stained with Zombie NIR fixable viability dye (BioLegend, San Diego, CA, USA) for 15 min at RT, then blocked with CD16/32 (clone 24G2, BD Biosciences, San Jose, CA, USA) and stained with the following antibodies: CD45 PerCP-Cy5.5 (clone 30 F11, eBioscience, San Diego, CA, USA), CD11b PECy7 (clone M1/70, eBioscience), Ly6G FITC (clone 1A8, BioLegend), F4/80 PE (clone A3-1, AbD Serotec, Oxford, UK), and Ly6C APC (clone AL-21, BD Biosciences) for 30 min at 4 °C. Cells were washed twice in PBS and fixed in 0.5% Ultra Pure formaldehyde (ThermoFisher Scientific, Waltham, MA, USA). Samples were acquired on BD FACSAria III equipped with 488- and 633-nm lasers with standard configuration. Data were analyzed using FCSExpress v5 (DeNovo Software Glendale, CA, USA).

Statistics

Statistical analyses were performed in GraphPad Prism software 5.03 (GraphPad Software, La Jolla, CA, USA) using either unpaired two-tailed t-test, one-way ANOVA or two-way ANOVA as appropriate. The statistical test used and n-numbers are indicated in each figure legend. *p*-values < 0.05 were considered statistically significant. All data are presented as mean $\pm$ standard deviation (SD).

Results

The Copper Complex Cu^{II}(at-sm) is Protective in *In Vitro* Models of Excitotoxicity and OGD

Excitotoxicity is a primary mechanism of neuronal injury following stroke. To determine the neuroprotective potential of Cu^{II}(at-sm) against excitotoxic insult, primary cortical neurons were treated with Cu^{II}(at-sm) in the presence of glutamate. Treating neurons with glutamate for 24 h resulted in approximately 40% reduction in cell viability as measured by the MTT assay (Fig. 1a). Co-treatment with Cu^{II}(at-sm) significantly improved the viability of glutamate-treated neurons, although the treatment did not entirely rescue the cells from excitotoxicity. At the tested concentrations, neuronal viability was not affected by Cu^{II}(at-sm) treatment alone. In a more relevant *in vitro* model of stroke, 24 h OGD caused approximately 50% cell death in N2a cultures (Fig. 1b). Pre-treatment with 0.1 μM Cu^{II}(at-sm) had a slight but significant protective effect in this assay.

Cu^{II}(at-sm) Reduces Ischemic Injury and Functional Impairment in a Transient Model of Cerebral Ischemia

Cu^{II}(at-sm) was tested firstly in the transient middle cerebral artery occlusion (MCAO) mouse model of cerebral ischemia. We found that Cu^{II}(at-sm) treatment (15 mg/kg, by oral gavage) both prior to MCAO, and at the start of reperfusion reduced infarct sizes 24 h later (Fig. 2a–b). Transient MCAO-induced functional impairment indexed by neuroscore was also prevented by pre-treatment of Cu^{II}(at-sm) (Fig. 2c) 24 h later.

Cu^{II}(at-sm) Confers a Beneficial Effect on the Outcome of Ischemic Stroke in a Permanent Model of Cerebral Ischemia

Cu^{II}(at-sm) was administered to mice by oral gavage immediately after permanent middle cerebral artery occlusion and the lesion volume was measured 24 h later by MRI. Cu^{II}(at-sm) administered at a dose of 60 mg/kg caused a significant reduction in the lesion volume (Fig. 3a–b). The locomotor activity of the ischemic mice was assessed using the latency-to-move test, which is reported to be affected for several days after ischemia [32]. Ischemic mice showed a significant reduction in the latency to move at 1 dpi, which was corrected to the levels of sham mice by Cu^{II}(at-sm) treatment (Fig. 3c). To confirm that the observed beneficial effects were related to copper delivery by Cu^{II}(at-sm), the ischemic brain tissues were analyzed for copper content by ICP-MS. When compared to vehicle-treated mice, the concentration of copper in the peri-ischemic area of the Cu^{II}(at-sm) treated mice was 57% higher (Fig. 3d), indicating efficient delivery of copper by the complex.





Fig. 1 Cu^{II}(atsm) is protective in *in vitro* models of stroke. **a** Primary cortical neurons were treated with Cu^{II}(atsm) in the presence of 400 μ M glutamate for 24 h, after which neuronal viability was measured by MTT reduction. **b** N2a cells were exposed to OGD for 24 h with or without 1 h Cu^{II}(atsm) pretreatment followed by MTT measurement for cell viability.

A control plate underwent similar assay, except the cells were incubated in regular culture conditions. Data show means $\pm$ standard deviation (SD) from one representative experiment. One-way ANOVA or paired t-test, * $p < 0.05$, *** $p < 0.001$. $n = 6$ in all groups

Fig. 2 Cu^{II}(atsm) is protective in transient ischemia. **a** Representative images of TTC stained brain sections at 1 dpi. **b** Quantitative analysis of infarct volume at 24 h after tMCAO. Mean $\pm$ standard deviation (SD). One-way ANOVA with Tukey post hoc test, * $p < 0.05$, ** $p < 0.01$ compared to vehicle, $n = 3$ –4/treatment group. **c** Transient MCAO-induced functional impairment indexed by neuroscore 1 dpi. Mean $\pm$ SD, one-way ANOVA with Tukey post hoc test, *** $p < 0.001$. $n = 3$ /treatment group






Fig. 3 Cu^{II}(atm) is protective in permanent ischemia and increases the brain copper content. **a** Representative MRI images of ischemic brains at 1 dpi. **b** Quantitative analysis of infarct volume at 24 h after pMCAO. Unpaired 2-tailed t-test, * $p < 0.05$. $n = 10$ in vehicle group, $n = 8$ in Cu^{II}(atm) group. **c** The latency-to-move was measured at 1 day after ischemia in sham operated and in mice subjected to pMCAO. Each mouse was tested twice and the data shows the average of two trials for

each mouse. Two-way ANOVA, * $p < 0.05$, ** $p < 0.01$. $n = 12$ in the sham vehicle group, $n = 12$ in the sham Cu^{II}(atm) group, $n = 8$ in the ischemic vehicle group, $n = 8$ in the ischemic Cu^{II}(atm) group. **d** The copper concentrations in the peri-ischemic brain areas were measured by ICP-MS at 3 dpi and are shown normalized to mass of the tissue $\pm$ standard deviation (SD). Unpaired 2-tailed t-test, * $p < 0.05$. $n = 6$ in vehicle group, $n = 4$ in Cu^{II}(atm) group

Cu^{II}(atm) Reduces CD45 Levels in the Ischemic Core

Previous studies have suggested that copper delivery may have anti-inflammatory effects in neurodegenerative diseases [33]. To assess the effect of copper delivery by Cu^{II}(atm) on neuroinflammation in the context of ischemic stroke, we first assessed astrocytic and myeloid cell activation in the ischemic brains by immunohistochemistry. Astrocytic activation as assessed by GFAP immunohistochemistry was not affected by Cu^{II}(atm) treatment in the peri-infarct area (data not shown). However, analyses of brains subjected to permanent ischemia revealed significant Cu^{II}(atm) induced alterations to the levels of CD45. CD45 is a marker expressed highly by monocytes and to a lower extent by microglia, in which expression is up-regulated after injury [34]. Copper delivery with Cu^{II}(atm) reduced the amount of CD45 immunoreactivity in the ischemic core both at 1 (Fig. 4a-b) and 3 dpi (Fig. 4c-d).

Cu^{II}(atm) Reduces Iba1 Immunoreactivity and Alters the Morphology of Iba1-Positive Cells in the Ischemic Brain

To extend our analyses of myeloid cell involvement in Cu^{II}(atm)-mediated protection from ischemic injury we

undertook a panel of immunohistological stainings in order to determine which cell types are affected by the treatment. While the immunoreactivities for CD68 (a marker of active phagocytosis) and Arginase-1 (a marker of alternatively activated cells) remained unaltered (data not shown), Iba1 levels in the peri-ischemic brains were altered by copper delivery. Iba1 is expressed by microglia and monocytes and its expression is reported to increase during ischemia [35]. It is considered one of the useful proteins for distinguishing microglia through immunostaining especially in stroke studies [35]. The Iba1 staining revealed a significant reduction of immunoreactivity by the Cu^{II}(atm) treatment at 3 dpi in mice subjected to pMCAO (Fig. 5a-b).

While measuring immunoreactivity following histological staining provides information about changes in the cells, it does not give detailed information about whether the change is related to the presence of more or less cells, larger or smaller cells or more or less intensively stained cells. Moreover, as microglial morphology is tightly coupled to their function we next assessed the effect of copper delivery on the structure of the Iba1-positive cells. The morphology of the Iba1 positive cells was analyzed as reported [30, 31]. The digital reconstruction (Fig. 5c) revealed that the morphology of Iba1-positive cells was altered by copper delivery in ischemic mice.




Fig. 4 Cu^{II}(atsm) reduces CD45 immunoreactivity in ischemic mice. **a** Typical example images of CD45 immunoreactivity in the ischemic lesion in vehicle-treated and Cu^{II}(atsm) treated mouse brains at 1 day after pMCAO. Scale bar = 20 μ m. **b** Quantitative analysis of CD45 immunoreactivity in the lesion at 1 dpi. Data are shown as means $\pm$ standard deviation (SD). Unpaired 2-tailed t-test, * p < 0.05. n = 7 in

both groups. **c** Typical example images of CD45 immunoreactivity in the ischemic lesion in vehicle-treated and Cu^{II}(atsm)-treated mouse brains at 3 dpi. Scale bar = 20 μ m. **d** Quantitative analysis of CD45 immunoreactivity in the lesion at 3 dpi. Data are shown as means $\pm$ SD. Unpaired 2-tailed t-test, * p < 0.05. n = 5 in both groups

Cu^{II}(atsm) did not affect cellular branching or processes (data not shown). However, despite the reduction in immunoreactivity (Fig. 5a–b) the treatment significantly increased the cellular area of the Iba1-positive cells (Fig. 5d).

Cu^{II}(atsm) Increases the Proportion of CD45^{low} CD11b⁺ Ly6G⁺ F4/80⁺ Cells in the Ischemic Brain

To create a multiparameter characterization of the cell types affected by Cu^{II}(atsm) during ischemia we isolated immune cells from the brain and applied flow cytometry for several

cellular markers. The gating strategies are shown in Fig. 6a. The cells were discriminated based on the expression of CD45, CD11b, F4/80, Ly6C and Ly6G (Fig. 6a–b). In comparison to sham mice, ischemia induced a 59% increase in CD45⁺CD11b⁺ lymphocytes (p = 0.001), and a 97% increase in Ly6G⁺ neutrophils (p < 0.001) (data not shown). Ischemia also induced a 95% increase in CD45^{high} CD11b⁺ Ly6G⁺ myeloid cells (p < 0.001), a 53% increase in the Ly6C^{high} CD45^{low} cells (p = 0.007), a 41% increase in Ly6C^{high} CD45^{high} cells, and a 70% increase in CD45^{high} F4/80⁺ cells (p < 0.001) (data not shown).




Fig. 5 Cu^{II}(atsm) reduces Iba1 immunoreactivity and alters the morphology of Iba1-positive cells in ischemic mice. **a** Typical example images of Iba1 immunoreactivity in the peri-ischemic brain area in vehicle-treated and Cu^{II}(atsm)-treated mouse brains at 3 dpi. Scale bar = 20 μ m. **b** Quantitative analysis of Iba1 immunoreactivity in the peri-ischemic brain area at 3 dpi. Data are shown as means $\pm$ standard

deviation (SD). Unpaired 2-tailed t-test, * p < 0.05. n = 5 in both groups. **c** Typical example images of the algorithm used to determine the morphology of Iba1 positive cells. Scale bar = 50 μ m. **d** Quantification of the cellular area of the Iba1 positive cells in the peri-ischemic brain areas of mice treated with Cu^{II}(atsm) at 1 dpi. Data are shown as means $\pm$ SD. Unpaired 2-tailed t-test, * p < 0.05. n = 8 in both groups




Fig. 6 Cu^{II}(atm) alters the ratios of myeloid cell in the ischemic hemisphere at 3 dpi. **a** Flow cytometric characterization strategy to identify cell populations. **b** Representative scatter plots showing gating process to ultimately distinguish CD45^{low}CD11b⁺ Ly6G⁻ and CD45^{high}CD11b⁺ Ly6G⁻ cell populations and their subpopulations of Ly6C and F4/80. Vehicle CD45 subpopulations displayed similar cell

distributions. **c** Quantified ratios of CD45^{high} and CD45^{low} CD11b⁺ Ly6G⁻ microglia in sham operated animals, and in mice that underwent pMCAO with either vehicle or Cu^{II}(atm) treatment. Mean $\pm$ standard deviation (SD), 1-way ANOVA, * $p < 0.05$, *** $p < 0.001$. $n = 6$ in stroke groups

The numbers of CD45^{low} CD11b⁺ Ly6G⁻ cells were reduced by 86% ($p < 0.001$) in ischemic brains (data not shown). Cu^{II}(atasm) treatment had a significant effect on this cell population, especially the cells that were Ly6G^{low} and F4/80⁺ (Fig. 6b). When compared to vehicle-treated ischemic mice, the percentages of resident CD45^{low} CD11b⁺ Ly6G⁻ cells were increased by 20%, while invading CD45^{high} CD11b⁺ Ly6G⁻ cells were reduced by 20% in the Cu^{II}(atasm)-treated mice at 3 dpi (Fig. 6b-c).

Copper Delivery by Cu^{II}(atasm) Reduces Additional Markers of Inflammation in the Ischemic Brain

To further assess the effect of copper delivery on the inflammatory milieu following ischemia, the immunoreactivity of p38 MAPK was analyzed by histochemical staining and the levels of six brain cytokines were analyzed by CBA. p38 MAPK is a key serine/threonine protein kinase that is an important contributor to increased microglial production of pro-inflammatory cytokines [36]. Staining for the active form of p38 MAPK in the brains of ischemic mice revealed that Cu^{II}(atasm) reduced its expression at 1 dpi (Fig. 7a-b).

CBA analyses showed that Cu^{II}(atasm) treatment at 1 dpi did not affect the amount of IL-6, IL-10, MCP-1, IFN- γ or TNF in the ischemic brain. However, copper delivery by Cu^{II}(atasm) reduced the protein level of IL-12 by 54% in the peri-ischemic area of the brain at 1 dpi (Fig. 7c). In contrast, IL-10 levels were increased by Cu^{II}(atasm) treatment at 3 dpi (Fig. 7d).

Discussion

Cu^{II}(atasm) has been shown to have protective effects in multiple animal models of chronic neurodegenerative diseases, such as ALS and PD [18, 20]. The compound is about to be tested in clinical trials in ALS patients (ClinicalTrials.gov identifier: NCT02870634). Interestingly, Cu^{II}(atasm) has a tendency to deliver copper into cells that suffer from a dysfunctional electron transport chain, indicating optimal pharmacokinetics in the ischemic brain [37]. Here, we report for the first time that Cu^{II}(atasm) is protective in acute brain injury, in two *in vivo* models of ischemic stroke. The protective effect is accompanied by beneficial modulation of the inflammatory milieu during stroke.

We report that Cu^{II}(atasm) reduces lesion volume and improves functional outcome in both transient and permanent models of ischemic stroke in mice. Demonstration of the therapeutic effect in two different models shows that protection is not dependent on mouse strain, duration of ischemia, or location of lesion. In the transient model the doses sufficient to elicit therapeutic effects were about half of that required in the permanent model of cerebral ischemia. The difference in effective dose may be connected to access to the ischemic area, as the reperfusion period in the transient model opens a circulatory connection to the injured site, mimicking recanalization therapy received by a human patient. The fact that Cu^{II}(atasm) reduced lesion volume and promoted functional recovery in both transient and permanent ischemia models suggests that it is a potent approach given the heterogeneous stroke subtypes observed in humans. In addition, using both permanent and




Fig. 7 Copper delivery by Cu^{II}(atasm) reduces markers of inflammation in the ischemic brain. **a** Typical example images of phosphorylated p38 MAPK immunoreactivity in the peri-ischemic brain area in vehicle-treated and Cu^{II}(atasm)-treated mouse brains at 1 day after pMCAO. Scale bar = 20 μ m. **b** Quantitative analysis of phosphorylated p38 MAPK immunoreactivity in the peri-ischemic brain area at 1 dpi. Data are shown as means $\pm$ standard deviation (SD). Unpaired 2-tailed t-test,

* $p < 0.05$. $n = 8$ in both groups. **c** The concentration of IL-12 in the peri-ischemic brain area was measured by CBA at 1 dpi. Data are shown as means $\pm$ SD. Unpaired 2-tailed t-test, * $p < 0.05$. $n = 5$ in vehicle and $n = 6$ in the Cu^{II}(atasm) group. **d** The concentration of IL-10 in the peri-ischemic brain area was measured by CBA at 3 dpi. Data are shown as means $\pm$ SD. Unpaired 2-tailed t-test, * $p < 0.05$. $n = 5$ in vehicle and $n = 6$ in the Cu^{II}(atasm) group

transient ischemia is a recommendation mentioned in STAIR criteria aiming to improve translation of preclinical stroke research [38].

As previously mentioned, studies with human patients have suggested an imbalance in copper homeostasis after cerebral ischemia [11, 12]. Elevated levels of copper were observed in the circulation of stroke patients in both studies, suggesting that copper is redistributed due to stroke-induced damage. Moreover, chronic intake of copper in the form of copper sulfate in the drinking water has been shown to exacerbate ischemic damage in mice, thereby indicating that increases in free copper exert toxic effects in the brain [13]. Here, we report that $\text{Cu}^{\text{II}}(\text{atsm})$ increased peri-ischemic concentrations of copper coincidentally with reduced lesion size and behavioural improvements. Formerly known as a hypoxia-imaging agent that releases copper mainly in the presence of a dysfunctional electron transport chain [37], we propose that short-term treatment with $\text{Cu}^{\text{II}}(\text{atsm})$ increased the copper content of the cells in the peri-ischemic resulting in observed protective and anti-inflammatory effects after stroke.

Neuronal excitotoxicity is one of the key components of stroke pathology leading to mitochondrial dysfunction [39]. It has been earlier described that copper has an essential function in protecting neurons against excitotoxicity through NMDAR receptor modulation [40]. In agreement with this, we demonstrate that the copper complex $\text{Cu}^{\text{II}}(\text{atsm})$ improved the viability of primary cortical neurons exposed to excitotoxic injury. However, it is likely that $\text{Cu}^{\text{II}}(\text{atsm})$ also affected secondary damage in the cells, rather than merely receptor activation, since copper delivery by $\text{Cu}^{\text{II}}(\text{atsm})$ is improved in the presence of mitochondrial dysfunction, and slight neuroprotection was also seen in OGD study using N2a cells [37]. For instance, studies with a transgenic mouse model of ALS have shown that $\text{Cu}^{\text{II}}(\text{atsm})$ treatment can increase both total amount of Cu/Zn superoxide dismutase (SOD1) and its copper content [41]. This might have a beneficial effect on the antioxidant defence of brain cells. In addition, lack of complete protection against excitotoxic insult and OGD might indicate a more complex scheme of protection *in vivo*, involving the interplay between neurons and microglia. Nevertheless, it is plausible that the neuroprotective effect seen in animal models of ischemia was at least partly caused by $\text{Cu}^{\text{II}}(\text{atsm})$ -mediated direct neuroprotective effect.

We have reported that the copper *bis*(thiosemicarbazonato) complexes mediate anti-inflammatory effects in neurodegenerative diseases (Choo et al., submitted). Thus, we characterized this anti-inflammatory effect in acute injury during stroke. Indeed, quantification of CD45 immunoreactivity revealed a significant reduction in this cell type in the ischemic core at 1 and 3 days after pMCAO, coinciding with reduced lesion volume and improved functional outcome. The cells in the ischemic core appeared $\text{CD45}^{\text{high}}$ -expressing, indicating that $\text{Cu}^{\text{II}}(\text{atsm})$ reduced the amount of infiltrating myeloid

cells into the ischemic area [42]. Because reduced infiltration of myeloid cells indicated altered initiation of post-stroke inflammation, we used multiple markers to specify the effect of $\text{Cu}^{\text{II}}(\text{atsm})$ on different inflammatory cell types in the pMCAO model. Based on immunohistochemical analyses of the peri-ischemic brain area, we report a $\text{Cu}^{\text{II}}(\text{atsm})$ -mediated reduction in Iba1 immunoreactivity. While previous studies have shown that Iba1 can be expressed by both microglia and invading peripheral inflammatory cells, the early time point of 3 days after ischemia used in the present study suggests that the observed reduction may be caused by reduced activation of resident microglia [35, 43].

Since microglial morphology and function are usually linked to each other [44], we next used an unbiased automated reconstructive procedure as to digitally reconstruct microglial morphology of the Iba1 positive cells following ischemia. $\text{Cu}^{\text{II}}(\text{atsm})$ increased the size of the somas of Iba1 positive microglia without affecting their processes or branching. Increased soma sizes have been reported to correlate with increased microglial activation [30]. Histologically, there may be separate phenotypic populations of microglial cells responding to $\text{Cu}^{\text{II}}(\text{atsm})$: those at an undifferentiated state displaying low Iba1 expression, and those with high Iba1 expression. Morphological assessment of the $\text{Iba1}^{\text{high}}$ cells revealed that the $\text{Iba1}^{\text{high}}$ cells are actually in a more activated state in $\text{Cu}^{\text{II}}(\text{atsm})$ -treated animals. These kinds of spatiotemporal differences in microglial responses to experimental treatments have been described earlier in the context of ischemic stroke, and are thought to arise from the heterogeneous nature of microglia [44, 45].

To calculate the true proportions of each cell type in the ischemic hemisphere, we used flow cytometry for multiple cellular markers. We report that 3 days after permanent MCAO, there was a strong infiltration of $\text{CD45}^{\text{high}} \text{CD11b}^+ \text{Ly6G}^-$ myeloid cells, $\text{CD45}^{\text{high}} \text{CD11b}^+ \text{Ly6G}^-$ lymphocytes and $\text{CD45}^{\text{high}} \text{CD11b}^+ \text{Ly6G}^+$ neutrophils. Infiltration of monocytes and lymphocytes is known to take place at this time point, whereas some controversy remains about the latency of neutrophil infiltration [46, 47]. In line with results from immunohistochemistry, $\text{Cu}^{\text{II}}(\text{atsm})$ significantly increased the amount of cells characterized by $\text{CD45}^{\text{low}} \text{CD11b}^+ \text{Ly6G}^-$, and reduced the proportion of $\text{CD45}^{\text{high}} \text{CD11b}^+ \text{Ly6G}^-$ cells 3 days after permanent MCAO. These results suggest that $\text{Cu}^{\text{II}}(\text{atsm})$ reduces the proportion of invading monocytes, and protects the endogenous microglia against ischemic insult. This may be related to the cellular protection observed in the quantification of the lesion size in MRI images.

P38 MAPK is a key mediator of microglial production of proinflammatory cytokines in the presence of multiple stressors [36]. In addition, inhibition of this kinase is protective in experimental models of stroke through multiple other pathways [48]. In the present study, we show that immunoreactivity of the active form of p38 was reduced in the ischemic

Cu^{II}(atsm)-treated animals. Based on morphology, these cells were microglial cells, giving further evidence of a reduced inflammatory state of the cells in the ischemic brain. At the same time, we also saw a reduction in IL-12 levels and a later increase in IL-10 levels. These alleviations in inflammatory signaling might be an important feature in Cu^{II}(atsm)-mediated protection of higher brain functions, as IL-12 has been associated with cognitive decline in stroke patients [49]. In addition, IL-10 deficiency has been previously shown to exacerbate ischemic brain damage, whereas common protectants such as minocycline increase IL-10-signaling [50, 51]. Taken together, these results suggest that Cu^{II}(atsm) has several inflammation-modulating actions in the ischemic brain.

Available treatment options for stroke are inadequate and those available have limited efficacy. This study reports the therapeutic actions of Cu^{II}(atsm) in two preclinical *in vivo* models of stroke, and characterizes the effects of copper modulation on immune responses occurring during experimental stroke. These results suggest that similarly to models of AD and peripheral inflammation (Choo et al., submitted), the copper *bis*(thiosemicarbazonato) complexes confer their beneficial effects at least partly through the modulation of inflammation, and specifically microglia, in ischemic brain injury. Since a copper *bis*(thiosemicarbazonato) complex is going to be tested clinically for ALS (ClinicalTrials.gov identifier: NCT02870634), it may shed light for the complex to be tested against neuronal damage after ischemic stroke clinically. This study also provides further support for the neurotherapeutic potential of copper modulation in brain disorders.

Acknowledgements We thank Ms Mirka Tikkanen for expert technical assistance. The study was supported by The Academy of Finland, The Sigrid Juselius Foundation, Orion Finland, the Australian Research Council, the National Health & Medical Research Council of Australia (NHMRC), the Cooperative Research Center for Mental Health, and National Natural Science Foundation of China (81271403, 81471304, 81571236).

Required Author Forms Disclosure forms provided by the authors are available with the online version of this article.

Compliance with Ethical Standards

Competing Financial Interests Dr. Bush is a shareholder in Prana Biotechnology Ltd, Cogstate Ltd, Mesoblast Ltd, NextVet Ltd, Brighton Biotech LLC, and Cogstate Ltd, and a consultant for Collaborative Medicinal Development Pty Ltd.

References

- Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. *J Transl Med* 2009;7: 97-5876-7-97.
- Solano Fonseca R, Mahesula S, Apple DM, Raghunathan R, Dugan A, Cardona A, et al. Neurogenic niche microglia undergo positional remodeling and progressive activation contributing to age-associated reductions in neurogenesis. *Stem Cells Dev* 2016;25(7):542-555.
- Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. *Science* 2011;333(6048):1456-1458.
- Lalancette-Hebert M, Swarup V, Beaulieu JM, Bohacek I, Abdelhamid E, Weng YC, et al. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. *J Neurosci* 2012;32(30):10383-10395.
- Jolivel V, Bicker F, Biname F, Ploen R, Keller S, Gollan R, et al. Perivascular microglia promote blood vessel disintegration in the ischemic penumbra. *Acta Neuropathol* 2015;129(2):279-295.
- Ma Y, Wang J, Wang Y, Yang GY. The biphasic function of microglia in ischemic stroke. *Prog Neurobiol* 2016.
- Thored P, Heldmann U, Gomes-Leal W, Gisler R, Darsalia V, Taneera J, et al. Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. *Glia* 2009;57(8):835-849.
- Lalancette-Hebert M, Gowing G, Simard A, Weng YC, Kriz J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. *J Neurosci* 2007;27(10):2596-2605.
- Zucconi GG, Cipriani S, Scattoni R, Balgkouranidou I, Hawkins DP, Ragnarsdottir KV. Copper deficiency elicits glial and neuronal response typical of neurodegenerative disorders. *Neuropathol Appl Neurobiol* 2007;33(2):212-225.
- Schrag M, Crofton A, Zabel M, Jiffry A, Kirsch D, Dickson A, et al. Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease. *J Alzheimers Dis* 2011;24(1):137-149.
- Kodali P, Chitta KR, Landero Figueroa JA, Caruso JA, Adeoye O. Detection of metals and metalloproteins in the plasma of stroke patients by mass spectrometry methods. *Metallomics* 2012;4(10):1077-1087.
- Lai M, Wang D, Lin Z, Zhang Y. Small molecule copper and its relative metabolites in serum of cerebral ischemic stroke patients. *J Stroke Cerebrovasc Dis* 2016;25(1):214-219.
- Jiang Y, Wang LP, Dong XH, Cai J, Jiang GJ, Zhang C, et al. Trace amounts of copper in drinking water aggravate cerebral ischemic injury via impairing endothelial progenitor cells in mice. *CNS Neurosci Ther* 2015;21(8):677-680.
- Grubman A, White AR, Liddell JR. Mitochondrial metals as a potential therapeutic target in neurodegeneration. *Br J Pharmacol* 2014;171(8):2159-2173.
- Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Chemy RA, et al. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. *J Biol Chem* 2008;283(8):4568-4577.
- Torres JB, Andreozzi EM, Dunn JT, Siddique M, Szanda I, Howlett DR, et al. PET imaging of copper trafficking in a mouse model of Alzheimer disease. *J Nucl Med* 2016;57(1):109-114.
- Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, et al. Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation. *Proc Natl Acad Sci USA* 2009;106(2):381-386.
- Soon CP, Donnelly PS, Turner BJ, Hung LW, Crouch PJ, Sherratt NA, et al. Diacetyl-bis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. *J Biol Chem* 2011;286(51):44035-44044.
- McAllum EJ, Lim NK, Hickey JL, Paterson BM, Donnelly PS, Li QX, et al. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener* 2013;14(7-8):586-590.
- Hung LW, Villemagne VL, Cheng L, Sherratt NA, Ayton S, White AR, et al. The hypoxia imaging agent CuII(atsm) is neuroprotective

- and improves motor and cognitive functions in multiple animal models of Parkinson's disease. *J Exp Med* 2012;209(4):837-854.
21. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. *J Immunol Methods* 1986;89(2):271-277.
 22. Tu W, Xu X, Peng L, Zhong X, Zhang W, Soundarapandian MM, et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. *Cell* 2010;140(2):222-234.
 23. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke* 1989;20(1):84-91.
 24. Dhungana H, Malm T, Denes A, Valonen P, Wojciechowski S, Magga J, et al. Aging aggravates ischemic stroke-induced brain damage in mice with chronic peripheral infection. *Aging Cell* 2013;12(5):472-476.
 25. Gingras BA, Suprunchuk T, Bayley CH. The preparation of some thiosemicarbazones and their copper complexes: Part III. 40(6) 1962;v62-161(Canadian Journal of Chemistry):1053-1059.
 26. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. *Stroke* 1986;17(3):472-476.
 27. Bargiotas P, Krenz A, Monyer H, Schwaninger M. Functional outcome of pannexin-deficient mice after cerebral ischemia. *Channels (Austin)* 2012;6(6):453-456.
 28. Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. *Stroke* 1993;24(1):117-121.
 29. Shuaib A, Xu Wang C, Yang T, Noor R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. *Stroke* 2002;33(12):3033-3037.
 30. Kongsui R, Johnson SJ, Graham BA, Nilsson M, Walker FR. A combined cumulative threshold spectra and digital reconstruction analysis reveal structural alterations of microglia within the prefrontal cortex following low-dose LPS administration. *Neuroscience* 2015;310:629-640.
 31. Muccigrosso MM, Ford J, Benner B, Moussa D, Burnsides C, Fenn AM, et al. Cognitive deficits develop 1 month after diffuse brain injury and are exaggerated by microglia-associated reactivity to peripheral immune challenge. *Brain Behav Immun* 2016;54:95-109.
 32. Lubjuhn J, Gastens A, von Wilpert G, Bargiotas P, Herrmann O, Murikinati S, et al. Functional testing in a mouse stroke model induced by occlusion of the distal middle cerebral artery. *J Neurosci Methods* 2009;184(1):95-103.
 33. Malm TM, Iivonen H, Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Kanninen K, et al. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. *J Neurosci* 2007;27(14):3712-3721.
 34. Ritzel RM, Patel AR, Grenier JM, Crapser J, Verma R, Jellison ER, et al. Functional differences between microglia and monocytes after ischemic stroke. *J Neuroinflammation* 2015;12:106-015-0329-1.
 35. Ito D, Tanaka K, Suzuki S, Dembo T, Fukuuchi Y. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. *Stroke* 2001;32(5):1208-1215.
 36. Bachstetter AD, Xing B, de Almeida L, Dimayuga ER, Watterson DM, Van Eldik LJ. Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta). *J Neuroinflammation* 2011;8:79-2094-8-79.
 37. Donnelly PS, Liddell JR, Lim S, Paterson BM, Cater MA, Savva MS, et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetyl-bis(4-methylthiosemicarbazone)copper(II). *Proc Natl Acad Sci U S A* 2012;109(1):47-52.
 38. Fisher M, Feuerstein G, Howells DW, Hum PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke* 2009;40(6):2244-2250.
 39. Stanika RI, Pivovarov NB, Brantner CA, Watts CA, Winters CA, Andrews SB. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. *Proc Natl Acad Sci USA* 2009;106(24):9854-9859.
 40. Gasperini L, Meneghetti E, Pastore B, Benetti F, Legname G. Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. *Antioxid Redox Signal* 2015;22(9):772-784.
 41. Roberts BR, Lim NK, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, et al. Oral treatment with Cu(II)(atm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. *J Neurosci* 2014;34(23):8021-8031.
 42. Greter M, Lelios I, Croxford AL. Microglia versus myeloid cell nomenclature during brain inflammation. *Front Immunol* 2015;6:249.
 43. Miro-Mur F, Perez-de-Puig I, Ferrer-Ferrer M, Urrea X, Justicia C, Chamorro A, et al. Immature monocytes recruited to the ischemic mouse brain differentiate into macrophages with features of alternative activation. *Brain Behav Immun* 2016;53:18-33.
 44. Zhang Z, Chopp M, Powers C. Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. *Brain Res* 1997;744(2):189-198.
 45. Schroeter M, Jander S, Witte OW, Stoll G. Heterogeneity of the microglial response in photochemically induced focal ischemia of the rat cerebral cortex. *Neuroscience* 1999;89(4):1367-1377.
 46. Zhou W, Liesz A, Bauer H, Sommer C, Lahrmann B, Valous N, et al. Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models. *Brain Pathol* 2013;23(1):34-44.
 47. Chu HX, Kim HA, Lee S, Moore JP, Chan CT, Vinh A, et al. Immune cell infiltration in malignant middle cerebral artery infarction: comparison with transient cerebral ischemia. *J Cereb Blood Flow Metab* 2014;34(3):450-459.
 48. Zhang XM, Zhang L, Wang G, Niu W, He Z, Ding L, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. *Neurochem Int* 2015;90:1-8.
 49. Narasimhalu K, Lee J, Leong YL, Ma L, De Silva DA, Wong MC, et al. Inflammatory markers and their association with post stroke cognitive decline. *Int J Stroke* 2015;10(4):513-518.
 50. Yang Y, Salayandia VM, Thompson JF, Yang LY, Estrada EY, Yang Y. Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery. *J Neuroinflammation* 2015;12:26-015-0245-4.
 51. Perez-de Puig I, Miro F, Salas-Perdomo A, Bonfill-Teixidor E, Ferrer-Ferrer M, Marquez-Kisinousky L, et al. IL-10 deficiency exacerbates the brain inflammatory response to permanent ischemia without preventing resolution of the lesion. *J Cereb Blood Flow Metab* 2013;33(12):1955-1966.